GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET
LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, will present at the Healthcare Virtual Conference Pat II, presented by Maxim Group LLC and hosted by M-Vest on Thursday, June 22, 2023 at 12:00 PM ET.
The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space. These include multiple therapeutic categories and emerging technologies, which presenting companies at this year's Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023. Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management. Maxim will also be hosting several topical industry panels that promise to be timely and engaging.
This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ("iNKT") cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
[email protected]
